In vitro activity of terbinafine (Lamisilr): An update

Journal of Dermatological Treatment

Volumn 9, Issue sup1, 1998, Pages S23-S28

  Ryder, ns ^a   Leitner, i ^a  

^a Novartis Research Institute   (Austria)

Author keywords

Candida; Dermatophytes; Susceptibility testing; Terbinafine

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; TERBINAFINE;

ASSAY; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CONFERENCE PAPER; CRYPTOCOCCUS; DERMATOMYCOSIS; DERMATOPHYTE; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; MALASSEZIA; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION; TRICHOSPORON BEIGELII; YEAST;

EID: 0031955311     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546639809160713     Document Type: Article

References (52)

1. Ryder N S, Mieth H. Allylamine antifungal drugs. Current topics in medical mycology, M Borgers, R Hay, M G Rinaldi. Springer-Verlag, New York 1992; vol 4: 158 – 88
2. Balfour J A, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in systemic mycoses. Drugs 1992; 43: 259 – 84
3. Shadomy S, Espinell-Ingroff A, Gebhart R J. In vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia 1985; 23: 125 – 32
4. Goudard M, Buffard Y, Ferrari H, Regli P. Spectre d'action in vitro d'un nouvel antifongique derivé de la naftifine: la terbinafine (SF 86-327). Pathol Biol Paris 1986; 34: 680 – 3
5. Petranyi G, Meingassner J G, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987; 31: 1365 – 8
6. Clayton Y M. The in vitro activity of terbinafine against uncommon fungal pathogens. Recent trends in the discovery, development and evaluation of antifungal agents, R A Fromtling. JR Prous Science Publishers, Barcelona 1987; 433 – 9
7. Ryder N S. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126 (suppl 39) 2 – 7
8. Ryder N S, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother 1997; 8: 275 – 87
9. Kemna M E, Elewski B E. A U.S. epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol 1996; 35: 539 – 42
10. Weitzman I, Summerbell R C. The dermatophytes. Clin Microbiol Rev 1995; 8: 240 – 59
11. Clayton Y M. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994; 130 (suppl 43) 7 – 8
12. Elewski B E. Clinical pearl: Diagnosis of onychomycosis. J Am Acad Dermatol 1995; 32: 500 – 1
13. Contet-Audonneau N, Schmutz J-L, Basile A-M, de Bievre C. A new agent of onychomycosis in the elderly: Onychocola canadensis. Eur J Dermatol 1997; 7: 115 – 17
14. Goudard M, Regli P, Buffard Y, Gabriel B. Sensibilité in vitro des Aspergillus à la terbinafine: étude comparative avec l'amphotericine B, la 5-fluorocytosine et le ketoconazole. Pathol Biol Paris 1988; 36: 129 – 43
15. Schmitt H J, et al. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 1988; 32: 780 – 1
16. Verweij P E, Cox N JM, Meis J FG. Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy. Eur J Clin Microbiol Infect Dis 1997; 16: 26 – 8
17. National Committee for Clinical Laboratory Standards. NCCLS, Villanova, Pa, USA 1995, Reference method for broth dilution antifungal susceptibility testing of yeasts: tentative standard M27-T.
18. Jung E G, Haas P J, Braütigam M, Weidinger G. Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole. Mycoses 1994; 37: 361 – 5
19. Kagawa S. Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis. Clin Exp Dermatol 1989; 14: 114 – 15
20. Ryder N S, Wagner S, Leitner I. In vitro activity of terbinafine against Candida and other yeasts by the NCCLS method. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. American Society for Microbiology, Washington, DC 1996; 91, Abstract E55
21. Sanz-Asenjo A, Heras-Tabernero J A, Vidal-Asensi S, Arjona-Manuel C. Healing of a multidrug resistant cutaneous cryptococcosis with oral terbinafine. Australasian J Dermatol 1997; 38 (suppl 2) 120
22. Mikami Y, Yazawa K, Uno J, Nishimura K. Comparison of antifungal activity of amphotericin B, miconazole, itraconazole, flucytosine and fluconazole against clinically isolated Cryptococcus neoformans by MIC and IC50 values, and their combination effects. Chemotherapy (Tokyo) 1991; 39: 1 – 8
23. Barrett-Bee K, Ryder N S. Biochemical aspects of ergosterol biosynthesis inhibition. Emerging targets for antibacterial and antifungal chemotherapy, J A Sutcliffe, N H Georgopapadakou. Chapman and Hall, New York 1992; 410 – 36
24. Ryder N S, Leitner I. Activity of terbinafine against Aspergillus in vitro. combination with amphotericin B or triazoles. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. American Society for Microbiology, Washington, DC 1996; 91, Abstract E54
25. Potential of terbinafine for combination with other antimycotics against Candida and Aspergillus. 1996, Abstracts book, Clinical Dermatology 2000, Vancouver, May 28-31.
26. Fothergill A W, et al. Combination antifungal susceptibility testing of terbinafine and the triazoles fluconazole and itraconazole. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. American Society for Microbiology, Washington, DC 1996; 91, Abstract E53
27. Rodero L, et al. In vitro activity of terbinafine in combination with triazole drugs against fluconazole resistant Candida species. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. American Society for Microbiology, Washington, DC 1996; 91, Abstract E56
28. Ryder N S, Leitner I. Synergy between terbinafine and fluconazole against azole- and multidrug-resistant Candida isolates. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. American Society for Microbiology, Washington, DC 1997, Abstract E-70
29. Engelkens H JH, Naafs B. Mycetoma. Br J Dermatol 1994; 131: 722 – 3
30. Cox N H, Irving B. Cutaneous 'ringworm' lesions of Scopulariopsis brevicaulis. Br J Dermatol 1993; 129: 726 – 8
31. Stiller M J, et al. Primary cutaneous infection by Aspergillus ustus in a 62-year-old liver transplant recipient. J Am Acad Dermatol 1994; 31: 344 – 7
32. Korting H C, Ollert M, Abeck D. German Collab Dermatophyte Drug Suscep, Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrob Agents Chemother 1995; 39: 1206 – 8
33. Butty P, Lebecq J C, Mallie M, Bastide J M. Evaluation of the susceptibility of dermatophytes to antifungal drugs: a new technique. J Med Vet Mycol 1995; 33: 403 – 9
34. Venugopal P V, Venugopal T V, Ramakrishna E S, Ilavarasin S. Antifungal activity of allylamines against agents of eumycetoma. Indian J Dermatol Venereol Leprol 1993; 59: 239 – 42
35. de Hoog G S, Matsumoto T, Matsuda T, Uijthof J MJ. Exophiala jeanselmei var. lecanii-corni, an etiologic agent of human phaeohyphomycosis, with report of a case. J Med Vet Mycol 1994; 32: 373 – 80
36. Hiratani T, Asagi Y, Yamaguchi H. Evaluation of in vitro antimycotic activity of terbinafine, a new allylamine agent. Jpn J Med Mycol 1991; 32: 323 – 32
37. Venugopal P V, Venugopal T V. Antifungal activity of allylamine derivatives. Indian J Med Res 1994; 99: 71 – 3
38. King D, et al. In vitro activities of econazole nitrate and terbinafine against fungal and bacterial pathogens commonly encountered in podiatric practice. Adv Ther 1994; 11: 120 – 31
39. Goudard M, Cordier C, Regli P. Sensibilité des Fusarium aux antifongiques: essais in vitro. Bull Soc Fr Mycol Med 1988; 17: 199 – 202
40. Ahmad A, et al. In vitro antifungal studies of terbinafine. Pakistan J Sci Ind Res 1989; 32: 737 – 9
41. Speeleveld E, et al. Susceptibility of clinical isolates of Fusarium to antifungal drugs. Mycoses 1996; 39: 37 – 40
42. Rubio M C, et al. In vitro evaluation of three new antifungal agents: amorolfine (Ro 14-4767/002), terbinafine (SF 86-327) and itraconazole (R 51,211). Rev Esp Quimioterap 1993; 6: 125 – 39
43. Meingassner J G, Frei R, Leitner I. Activity of terbinafine against isolates of Paecilomyces lilacinus resistant to amphotericin B, miconazole, fluconazole and itraconazole. Abstracts of Second International Summit on Cutaneous Antifungal Therapy, Boston, MA, 1994
44. Norden G, et al. Cure of zygomycosis caused by a lipase-producing Rhizopus rhizopodiformis strain in a renal transplant patient. Scand J Infect Dis 1991; 23: 377 – 82
45. Dixon D M, Polak A. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy 1987; 33: 129 – 40
46. Polak A, Dixon D M. Loss of melanin in Wangiella dermatiditis does not result in greater susceptibility to antifungal agents. Antimicrob Agents Chemother 1989; 33: 1639 – 40
47. Bryan C S, Smith C W, Berg D E, Karp R B. Curvularia-lunata endocarditis treated with terbinafine - case report. Clin Infect Dis 1993; 16: 30 – 2
48. Wong P K, Ching W TW, Kwon-Chung K J, Meyer R D. Disseminated Phialophora parasitica infection in humans: case report and review. Rev Infect Dis 1989; 11: 770 – 5
49. Schaude M, Ackerbauer H, Mieth H. Inhibitory effect of antifungal agents on germ tube formation in Candida albicans. Mykosen 1987; 30: 281 – 7
50. Regli P, Goudard M, Ferrari H. In vitro comparative study of the susceptibility of Malassezia (Pityrosporum) to new antifungal agents terbinafine, ciclopiroxolamine, amorolfine. Bull Soc Fr Mycol Med 1989; 18: 51 – 4
51. Uchida K, Yamaguchi H. In vitro anti-Malassezia activity of terbinafine. Jpn J Med Mycol 1991; 32: 343 – 6
52. Sansom J E, Burton J L, Leeming J P. Effects of terbinafine on Malassezia furfur populations on human skin. Br J Dermatol 1995; 132: 650, (Abstract).